Safety and Efficacy Study of a Dual PI3K Delta/Gamma Inhibitor in T-cell Lymphoma
Summary
The lay summary the sponsor registered on ClinicalTrials.gov.
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Auris Huen, MD
MD Anderson Cancer Center, Houston, Tx.
Principal Investigator
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
8 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- City of Hope
Duarte, California, United States
- Chao Family Comprehensive Cancer Center University of California Irvine
Orange, California, United States
- University of Colorado Cancer Center
Aurora, Colorado, United States
- Emory University School of Medicine
Atlanta, Georgia, United States
- University of Michigan Comprehensive Cancer Center
Ann Arbor, Michigan, United States
- Karmanos Cancer Institute
Detroit, Michigan, United States
- University Hospitals Cleveland Medical Center
Cleveland, Ohio, United States
- Md Anderson Cancer Center
Houston, Texas, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 30 Sept 2015
- Primary completion
- 31 Mar 2018
- Completion
- 10 Dec 2018
- Last update posted
- 13 Jan 2020
- Registered enrollment
- 58
- Registry id
- NCT02567656
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.